Safety of Bisphosphonates in the Treatment of Osteoporosis

Robert R. Recker, E. Michael Lewiecki, Paul D. Miller, James Reiffel

Research output: Contribution to journalArticle

74 Scopus citations

Abstract

In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).

Original languageEnglish (US)
Pages (from-to)S22-S32
JournalAmerican Journal of Medicine
Volume122
Issue number2 SUPPL.
DOIs
StatePublished - Feb 3 2009

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this